Vivos Therapeutics (NASDAQ:VVOS) Stock Rating Lowered by Alliance Global Partners

Vivos Therapeutics (NASDAQ:VVOS) was downgraded by Alliance Global Partners from a “buy” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat.com reports.

Separately, Ascendiant Capital Markets reduced their price objective on shares of Vivos Therapeutics from $6.60 to $6.20 and set a “buy” rating for the company in a research note on Tuesday, April 15th.

Vivos Therapeutics Trading Up 0.5%

Shares of NASDAQ:VVOS opened at $2.09 on Tuesday. The company has a 50 day moving average of $2.69 and a 200 day moving average of $3.53. The stock has a market cap of $12.31 million, a P/E ratio of -0.37 and a beta of 7.31. Vivos Therapeutics has a 12 month low of $1.91 and a 12 month high of $6.28.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $3.63 million. Vivos Therapeutics had a negative net margin of 86.19% and a negative return on equity of 335.04%. During the same period in the prior year, the firm posted ($1.63) EPS. On average, equities analysts forecast that Vivos Therapeutics will post -1.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vivos Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of VVOS. Cutter & CO Brokerage Inc. bought a new stake in shares of Vivos Therapeutics in the 4th quarter worth approximately $163,000. Commonwealth Equity Services LLC lifted its holdings in shares of Vivos Therapeutics by 23.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock worth $112,000 after acquiring an additional 5,000 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Vivos Therapeutics by 55.6% in the 4th quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock worth $192,000 after acquiring an additional 16,025 shares during the last quarter. Anson Funds Management LP bought a new stake in shares of Vivos Therapeutics in the 4th quarter worth approximately $1,041,000. Finally, EWA LLC bought a new stake in shares of Vivos Therapeutics in the 1st quarter worth approximately $30,000. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.